NasdaqCM:PAVM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PAVmed Inc. operates as a medical device company in the United States. More Details


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has PAVmed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PAVM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

PAVM

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

86.8%

PAVM

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: PAVM exceeded the US Medical Equipment industry which returned 16.5% over the past year.

Return vs Market: PAVM exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

PAVMIndustryMarket
7 Day-1.6%-1.7%-0.8%
30 Day-6.8%-3.5%-5.7%
90 Day-15.2%12.2%8.6%
1 Year86.8%86.8%17.5%16.5%16.4%13.8%
3 Year-68.0%-68.0%70.0%65.6%36.9%27.8%
5 Yearn/a139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is PAVmed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PAVmed undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether PAVmed is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PAVmed has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is PAVmed forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

31.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAVM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PAVM's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PAVM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PAVmed performed over the past 5 years?

-41.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAVM is currently unprofitable.

Growing Profit Margin: PAVM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAVM is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.

Accelerating Growth: Unable to compare PAVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAVM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: PAVM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is PAVmed's financial position?


Financial Position Analysis

Short Term Liabilities: PAVM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PAVM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PAVM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PAVM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAVM has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: PAVM is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is PAVmed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PAVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAVM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAVM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PAVM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Lishan Aklog (54 yo)

6.25yrs

Tenure

US$677,850

Compensation

Dr. Lishan Aklog, M.D, serves as Director at ContraFect Corporation since June 14, 2020. Dr. Aklog has also served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018. Dr. Aklog se ...


CEO Compensation Analysis

Compensation vs Market: Lishan's total compensation ($USD677.85K) is about average for companies of similar size in the US market ($USD604.44K).

Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Lishan Aklog
Chairman & CEO6.25yrsUS$677.85k11.1%
$ 10.0m
Dennis McGrath
President1.5yrsUS$517.50k1.58%
$ 1.4m
Brian deGuzman
Chief Medical Officer & Executive VP of Clinical Affairs5.92yrsUS$455.31k0%
$ 0
Mike Havrilla
Director of Investor Relationsno datano datano data
Shaun O'Neil
Chief Commercial Officer2.17yrsno datano data

4.0yrs

Average Tenure

55yo

Average Age

Experienced Management: PAVM's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lishan Aklog
Chairman & CEO6.25yrsUS$677.85k11.1%
$ 10.0m
Ronald Sparks
Independent Director5.67yrsUS$65.00k0%
$ 0
David Weild
Independent Director5.58yrsUS$67.50k0%
$ 0
Todd Rosengart
Member of Medical Advisory Board5.83yrsno datano data
James Cox
Independent Director5.67yrsUS$52.50k0%
$ 0
Marc Gerdisch
Member of Medical Advisory Board5.83yrsno datano data
Philip Stieg
Member of Medical Advisory Board5.67yrsno datano data
Albert Chin
Member of Medical Advisory Board5.67yrsno datano data
Michael Glennon
Independent Vice Chairman5.92yrsUS$26.25k0%
$ 0
David Battleman
Independent Director3.08yrsUS$60.00k0%
$ 0
Timothy Murphy
Member of Medical Advisory Board5.83yrsno datano data
Christopher Hartnick
Member of Medical Advisory Board3.83yrsno datano data

5.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: PAVM's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.9%.


Top Shareholders

Company Information

PAVmed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PAVmed Inc.
  • Ticker: PAVM
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$89.682m
  • Shares outstanding: 50.10m
  • Website: https://www.pavmed.com

Number of Employees


Location

  • PAVmed Inc.
  • One Grand Central Place
  • Suite 4600
  • New York
  • New York
  • 10165
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAVMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2016
1P5BST (Boerse-Stuttgart)YesCommon StockDEEURJul 2016

Biography

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 04:52
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.